Señales en vivo de CYTH | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	28 089.00
Volumen promedio	100 379
Capitalización de mercado	36.18M
EPS	$0 ( 2024-03-18 )
Próxima fecha de ganancias	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.020
ATR14	$0.0120 (0.95%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-13	Sieger Markus	Buy	14 004	Common Stock
2024-02-13	Ostronic Francis Patrick	Buy	8 703	Common Stock
2024-02-13	Toig Randall M.	Buy	7 516	Common Stock
2024-02-13	Strattan Ce Rick	Buy	6 963	Common Stock
2024-02-13	Wong Vivien	Buy	6 330	Common Stock

INSIDER POWER
50.71
Last 99 transactions
Buy: 16 269 213 \| Sell: 5 479 045

Cyclo Therapeutics, Inc. Correlación

10 Correlaciones Más Positivas
STRO	0.944
ASPU	0.94
LSXMK	0.922
LSXMA	0.922
PRTG	0.917
NAKD	0.917
BOCH	0.915
SIRI	0.911
ACRX	0.91
BFRI	0.91

10 Correlaciones Más Negativas
PAE	-0.928
RMRM	-0.927
APOP	-0.916
PESI	-0.907
EBSB	-0.905
INTA	-0.905
LMNR	-0.905
NCAC	-0.903
NVDA	-0.903
FTNT	-0.902

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cyclo Therapeutics, Inc. Finanzas

Annual	2023
Ingresos:	$1.08M
Beneficio Bruto:	$-2.41M (-223.91 %)
EPS:	$-1.230

FY	2023
Ingresos:	$1.08M
Beneficio Bruto:	$-2.41M (-223.91 %)
EPS:	$-1.230

FY	2022
Ingresos:	$1.38M
Beneficio Bruto:	$1.24M (89.90 %)
EPS:	$-1.810

FY	2021
Ingresos:	$1.59M
Beneficio Bruto:	$1.43M (90.16 %)
EPS:	$-2.24

Financial Reports:

No articles found.

Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.